THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 114 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $164 | -35.4% | 18,994 | -22.5% | 0.00% | – |
| Q2 2023 | $254 | -30.4% | 24,506 | -27.2% | 0.00% | – |
| Q1 2023 | $365 | -25.5% | 33,671 | -22.9% | 0.00% | -100.0% |
| Q4 2022 | $490 | -99.9% | 43,654 | -0.0% | 0.00% | 0.0% |
| Q3 2022 | $443,000 | +12.4% | 43,659 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $394,000 | +15.2% | 43,518 | +21.5% | 0.00% | – |
| Q1 2022 | $342,000 | -13.6% | 35,817 | +0.0% | 0.00% | – |
| Q4 2021 | $396,000 | +85.0% | 35,806 | +23.7% | 0.00% | – |
| Q3 2021 | $214,000 | -69.1% | 28,951 | -39.3% | 0.00% | -100.0% |
| Q2 2021 | $693,000 | -18.0% | 47,694 | +15.2% | 0.00% | 0.0% |
| Q1 2021 | $845,000 | +14.8% | 41,400 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $736,000 | +20.3% | 41,400 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $612,000 | -29.6% | 41,400 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $869,000 | -10.9% | 41,400 | -1.9% | 0.00% | 0.0% |
| Q1 2020 | $975,000 | -10.8% | 42,200 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $1,093,000 | +16.6% | 42,200 | -12.3% | 0.00% | 0.0% |
| Q3 2019 | $937,000 | +36.4% | 48,100 | +14.3% | 0.00% | 0.0% |
| Q2 2019 | $687,000 | -28.0% | 42,100 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $954,000 | -11.4% | 42,100 | 0.0% | 0.00% | -50.0% |
| Q4 2018 | $1,077,000 | -28.8% | 42,100 | -9.1% | 0.00% | 0.0% |
| Q3 2018 | $1,513,000 | +44.1% | 46,300 | 0.0% | 0.00% | +100.0% |
| Q2 2018 | $1,050,000 | -6.5% | 46,300 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $1,123,000 | -13.0% | 46,300 | 0.0% | 0.00% | -50.0% |
| Q4 2017 | $1,291,000 | -18.5% | 46,300 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,585,000 | -14.1% | 46,300 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,845,000 | +18.2% | 46,300 | +9.2% | 0.00% | 0.0% |
| Q1 2017 | $1,561,000 | +28.2% | 42,401 | +11.0% | 0.00% | 0.0% |
| Q4 2016 | $1,218,000 | -12.0% | 38,200 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $1,384,000 | +120.0% | 38,200 | +37.9% | 0.00% | +100.0% |
| Q2 2016 | $629,000 | +20.7% | 27,700 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $521,000 | +36.4% | 27,700 | +18.9% | 0.00% | 0.0% |
| Q4 2015 | $382,000 | +49.2% | 23,300 | 0.0% | 0.00% | – |
| Q3 2015 | $256,000 | -26.6% | 23,300 | -13.2% | 0.00% | -100.0% |
| Q2 2015 | $349,000 | – | 26,830 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |